Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Immatics stock
Learn how to easily invest in Immatics stock.
Immatics is a biotechnology business based in the US. Immatics shares (IMTX) are listed on the NASDAQ and all prices are listed in US Dollars. Immatics employs 382 staff and has a trailing 12-month revenue of around $150.9 million.
How to buy Immatics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – IMTX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Easy to use platform with low fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Immatics stock price (NASDAQ: IMTX)Use our graph to track the performance of IMTX stocks over time.
Immatics shares at a glance
|Latest market close||$8.34|
|52-week range||$5.75 - $13.60|
|50-day moving average||$9.25|
|200-day moving average||$9.60|
|Wall St. target price||$19.57|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.57|
Buy Immatics stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Immatics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Immatics price performance over time
|1 week (2023-01-31)||2.84%|
|1 month (2023-01-06)||-11.65%|
|3 months (2022-11-07)||-20.11%|
|6 months (2022-08-05)||-33.01%|
|1 year (2022-02-07)||-12.85%|
|2 years (2021-02-05)||-24.52%|
|3 years (2020-02-03)||N/A|
|5 years (2018-02-03)||N/A|
Is Immatics stock undervalued or overvalued?
Valuing Immatics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Immatics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Immatics's P/E ratio
Immatics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, Immatics shares trade at around 15x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Immatics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $17.7 million.
The EBITDA is a measure of a Immatics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$150.9 million|
|Operating margin TTM||9.18%|
|Gross profit TTM||$-52,811,000|
|Return on assets TTM||3.13%|
|Return on equity TTM||45.83%|
|Market capitalisation||$633.4 million|
TTM: trailing 12 months
Immatics share dividends
We're not expecting Immatics to pay a dividend over the next 12 months.
Immatics share price volatility
Over the last 12 months, Immatics's shares have ranged in value from as little as $5.75 up to $13.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immatics's is 0.5555. This would suggest that Immatics's shares are less volatile than average (for this exchange).
Immatics N. V. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate.
Immatics in the news
12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds
10 Best Healthcare Stocks For the Long Term
Frequently asked questionsWhat percentage of Immatics is owned by insiders or institutions?
Currently 29.921% of Immatics shares are held by insiders and 29.319% by institutions. How many people work for Immatics?
Latest data suggests 382 work at Immatics. When does the fiscal year end for Immatics?
Immatics's fiscal year ends in December. Where is Immatics based?
Immatics's address is: Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076 What is Immatics's ISIN number?
Immatics's international securities identification number is: NL0015285941
More guides on Finder
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert